Favicon
Favicon

Charles Evavold Awarded Karin Grunebaum Cancer Research Foundation Faculty Research Fellowship

Date: June 25, 2024 By: Nick Kolev

Ragon faculty member and Early Independence Fellow Charles Evavold, PhD, has been selected as the recipient of the prestigious 2024-2025 Karin Grunebaum Cancer Research Foundation Faculty Research Fellowship at Harvard Medical School. The fellowship selection committee was deeply impressed by Evavold’s accomplishments and his potential for leadership in cancer research.

Evavold was also invited to present his research at the semiannual meeting of the board of the Karin Grunebaum Cancer Research Foundation, which will be held at Boston University Medical Center on Friday, June 14. 

Evavold is a Principal Investigator at the Ragon Institute and an Instructor at Harvard Medical School. His research focuses on synthetic immunity and cell death regulation, studying fundamental cellular decision-making using cell death programs as a model system. His lab aims to uncover novel regulation in these processes, combining genomic or chemical perturbations with synthetic biology models.

The Karin Grunebaum Cancer Research Foundation is dedicated to advancing cancer research and supporting scientists who show exceptional promise in this vital area of medical science.

Congratulations, Dr. Evavold!

More News

Groundbreaking Discovery Uncovers Achilles’ Heel of Malaria Parasite

A collaborative effort between researchers from Uganda, Tanzania, the US, Spain, and Denmark has resolved a longstanding question in malaria research: Do individuals living in regions with continuous malaria transmission develop broadly neutralizing antibodies (BnAbs) against the malaria parasite? The answer is yes.

Press Releases

Ringel Lab Study Reveals Age-Related Decline in Tumor-Fighting T Cells and Its Impact on Cancer Treatment

Researchers at the Ragon Institute of Mass General Brigham, MIT, and Harvard have uncovered critical insights into how aging impairs the immune system’s ability to fight cancer.